/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Stem Cells is an early-stage landscape with 10 programs across 14 companies. The most active players are Guangdong ProCapZoom Biosciences Co., Ltd..
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Bubble size = clinical trials
Key Players
Pipeline
Analysis
71%
Small molecule
5 of 7 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.
Analysis
176
clinical trials
Clinical Trials
176 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)